Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01584648
Registration number
NCT01584648
Ethics application status
Date submitted
23/04/2012
Date registered
25/04/2012
Date last updated
17/02/2021
Titles & IDs
Public title
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Query!
Scientific title
A Phase III, Randomized, Double-blinded Study Comparing the Combination of the BRAF Inhibitor, Dabrafenib and the MEK Inhibitor, Trametinib to Dabrafenib and Placebo as First-line Therapy in Subjects With Unresectable (Stage IIIC) or Metastatic (Stage IV) BRAF V600E/K Mutation-positive Cutaneous Melanoma
Query!
Secondary ID [1]
0
0
2011-006087-49
Query!
Secondary ID [2]
0
0
115306
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Melanoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Malignant melanoma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Dabrafenib
Treatment: Drugs - Trametinib
Treatment: Drugs - Trametinib placebo
Experimental: Dabrafenib + Trametinib - Dabrafenib and Trametinib combination
Active comparator: Dabrafenib + Placebo - Dabrafenib and Trametinib placebo
Treatment: Drugs: Dabrafenib
Dabrafenib 150 mg twice daily
Treatment: Drugs: Trametinib
Trametinib 2 mg once daily
Treatment: Drugs: Trametinib placebo
Dabrafenib 150 mg twice daily and trametinib placebo
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression-Free Survival (PFS) as Assessed by the Investigator
Query!
Assessment method [1]
0
0
PFS is defined as the interval between the date of randomization and the earliest date of PD or death due to any cause. PD was based on radiographic or photographic evidence, and assessments were made by the investigator according to RECIST, version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started. In addition, the sum must have an absolute increase from nadir of 5 mm. The appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation, was also included as PD. Participants who received anti-cancer therapy prior to the date of documented events, were censored at the last adequate assessment prior to the initiation of therapy. If the participant did not have documented progression or death, PFS was censored at the date of the last adequate assessment.
Query!
Timepoint [1]
0
0
From randomization until the earliest date of disease progression (PD) or death due to any cause (up to approximately 6 years)
Query!
Secondary outcome [1]
0
0
Overall Survival (OS)
Query!
Assessment method [1]
0
0
OS is defined as the interval of time between the date of randomization and the date of death due to any cause. For the participants who did not die, overall survival was censored at the date of last contact.
Query!
Timepoint [1]
0
0
From the date of randomization until date of death due to any cause (up to approximately 6 years)
Query!
Secondary outcome [2]
0
0
Objective Response Rate (ORR) as Assessed by the Investigator
Query!
Assessment method [2]
0
0
ORR is defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR). A participant was defined as a responder if he/she sustained a complete response (CR: the disappearance of all target lesions and any pathological lymph nodes must have a short axis of \<10 mm and the disappearance of all non-target lesions) or partial response (PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters or the persistence of 1 or more non-target lesions or lymph nodes identified as a site of disease at Baseline with a short axis of =10mm). Only descriptive analysis performed.
Query!
Timepoint [2]
0
0
From randomization until the first documented complete response or partial response (up to approximately 6 years)
Query!
Secondary outcome [3]
0
0
Duration of Response (DoR)
Query!
Assessment method [3]
0
0
Duration of response is defined as the time from the first documented complete response (CR: the disappearance of all target lesions and any pathological lymph nodes must have a short axis of \<10 mm and the disappearance of all non-target lesions) or partial response (PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters or the persistence of 1 or more non-target lesions or lymph nodes identified as a site of disease at Baseline with a short axis of =10mm) until disease progression (PD) or death due to any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5mm or the appearance of one or more new lesions, or the worsening of non target lesions significant enough to require study treatment discontinuation. PD was based on the radiological evidence by investigator. Only descriptive analysis performed.
Query!
Timepoint [3]
0
0
From the time of the first documented response (CR or PR) until disease progression (up to approximately 6 years)
Query!
Secondary outcome [4]
0
0
Trametinib Pharmacokinetic Concentrations
Query!
Assessment method [4]
0
0
Blood samples were collected for Pharmacokinetic (PK) analysis in all participants. Three blood samples were collected at Week 8: pre-dose, 1-3 hours post dose, and 4-6 hours post dose. One pre-dose blood sample was obtained at Weeks 16 and 24. Only descriptive analysis performed.
Query!
Timepoint [4]
0
0
Week 8 (0, 1-3, 4-6 hours post dose), Weeks 16 and 24 (0 hour pre-dose)
Query!
Secondary outcome [5]
0
0
Dabrafenib and Dabrafenib Metabolites (Hydroxy-, Carboxy- and Desmethyl-Dabrafenib) Concentrations
Query!
Assessment method [5]
0
0
Blood samples were collected for PK analysis in all participants. Three blood samples were collected at Week 8: pre-dose, 1-3 hours post dose, and 4-6 hours post dose. One pre-dose blood sample was obtained at Weeks 16 and 24. Plasma concentrations of Dabrafenib (GSK2118436) and its metabolites (Hydroxy-Dabrafenib (GSK2285403), Carboxy-Dabrafenib (GSK2298683), and Desmethyl-Dabrafenib (GSK2167542)) were determined using the currently approved analytical methodology. Only descriptive analysis performed.
Query!
Timepoint [5]
0
0
Week 8 (0, 1-3, 4-6 hours post dose), Weeks 16 and 24 (0 hour pre-dose)
Query!
Secondary outcome [6]
0
0
Number of Participants With Adverse Events and Serious Adverse Events
Query!
Assessment method [6]
0
0
Analysis of absolute and relative frequencies for Adverse Event (AE) and Serious Adverse Event (SAE) by primary System Organ Class (SOC) to characterize the safety of dabrafenib and trametinib combination therapy through the monitoring of relevant clinical and laboratory safety parameters. In addition, new malignancies and AEs possibly related to study treatment were collected even if they occurred more than 30 days post-treatment. Only descriptive analysis performed.
Query!
Timepoint [6]
0
0
From the time the first dose of study treatment administered until 30 days after discontinuation of study treatment (up to approximately 6 years).
Query!
Eligibility
Key inclusion criteria
* Histologically confirmed cutaneous melanoma that is either Stage IIIC (unresectable) or Stage IV (metastatic), and determined to be BRAF V600E/K mutation-positive using the bioMerieux (bMx) investigational use only (IUO) THxID BRAF Assay (IDE: G120011). The assay will be conducted by a central reference laboratory. Subjects with ocular or mucosal melanoma are not eligible.
* The subject must have a radiologically measurable tumor
* The subject is able to carry out daily life activities without significant difficulty (ECOG performance status score of 0 or 1).
* Able to swallow and retain oral medication
* Sexually active subjects must use acceptable methods of contraception during the course of the study
* Adequate organ system function and blood counts
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Prior treatment with a BRAF or a MEK inhibitor
* Prior systemic anti-cancer treatment for Stage IIIC (unresectable) or Stage IV (metastatic) melanoma. Prior systemic treatment in the adjuvant setting is allowed. (Note: Ipilimumab treatment must end at least 8 weeks prior to randomization.)
* The subject has received major surgery or certain tyes of cancer therapy with 21 days of starting treatment
* Current use of prohibited medication listed in the protocol
* Left ventricular ejection fraction less than the lower limit of normal
* Uncontrolled blood pressurl
* History or current evidence of retinal vein occlusion or central serous retinopathy
* Brain metastases unless previously treated with surgery or stereotactic radiosurgery and the disease has been stable for at least 12 weeks
* The subject is pregnant or nursing
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
4/05/2012
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
28/02/2019
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
423
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
Novartis Investigative Site - North Sydney
Query!
Recruitment hospital [2]
0
0
Novartis Investigative Site - Westmead
Query!
Recruitment hospital [3]
0
0
Novartis Investigative Site - Woolloongabba
Query!
Recruitment hospital [4]
0
0
Novartis Investigative Site - Adelaide
Query!
Recruitment hospital [5]
0
0
Novartis Investigative Site - Heidelberg
Query!
Recruitment hospital [6]
0
0
Novartis Investigative Site - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
2060 - North Sydney
Query!
Recruitment postcode(s) [2]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [3]
0
0
4102 - Woolloongabba
Query!
Recruitment postcode(s) [4]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [5]
0
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [6]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Illinois
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Indiana
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Massachusetts
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
New York
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Ohio
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Pennsylvania
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
South Carolina
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Tennessee
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Texas
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Virginia
Query!
Country [14]
0
0
Argentina
Query!
State/province [14]
0
0
Buenos Aires
Query!
Country [15]
0
0
Canada
Query!
State/province [15]
0
0
Alberta
Query!
Country [16]
0
0
Canada
Query!
State/province [16]
0
0
Ontario
Query!
Country [17]
0
0
Canada
Query!
State/province [17]
0
0
Quebec
Query!
Country [18]
0
0
France
Query!
State/province [18]
0
0
Bordeaux
Query!
Country [19]
0
0
France
Query!
State/province [19]
0
0
Boulogne-Billancourt
Query!
Country [20]
0
0
France
Query!
State/province [20]
0
0
Lyon Cedex 08
Query!
Country [21]
0
0
France
Query!
State/province [21]
0
0
Marseille cedex 5
Query!
Country [22]
0
0
France
Query!
State/province [22]
0
0
Paris Cedex 10
Query!
Country [23]
0
0
France
Query!
State/province [23]
0
0
Paris
Query!
Country [24]
0
0
France
Query!
State/province [24]
0
0
Toulouse Cedex
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Vandoeuvre les Nancy
Query!
Country [26]
0
0
Germany
Query!
State/province [26]
0
0
Baden-Wuerttemberg
Query!
Country [27]
0
0
Germany
Query!
State/province [27]
0
0
Bayern
Query!
Country [28]
0
0
Germany
Query!
State/province [28]
0
0
Hessen
Query!
Country [29]
0
0
Germany
Query!
State/province [29]
0
0
Niedersachsen
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Nordrhein-Westfalen
Query!
Country [31]
0
0
Germany
Query!
State/province [31]
0
0
Rheinland-Pfalz
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
Saarland
Query!
Country [33]
0
0
Germany
Query!
State/province [33]
0
0
Sachsen-Anhalt
Query!
Country [34]
0
0
Germany
Query!
State/province [34]
0
0
Sachsen
Query!
Country [35]
0
0
Germany
Query!
State/province [35]
0
0
Schleswig-Holstein
Query!
Country [36]
0
0
Germany
Query!
State/province [36]
0
0
Thueringen
Query!
Country [37]
0
0
Germany
Query!
State/province [37]
0
0
Berlin
Query!
Country [38]
0
0
Greece
Query!
State/province [38]
0
0
Athens
Query!
Country [39]
0
0
Greece
Query!
State/province [39]
0
0
N. Faliro
Query!
Country [40]
0
0
Greece
Query!
State/province [40]
0
0
Thessaloniki
Query!
Country [41]
0
0
Italy
Query!
State/province [41]
0
0
Lazio
Query!
Country [42]
0
0
Italy
Query!
State/province [42]
0
0
Liguria
Query!
Country [43]
0
0
Italy
Query!
State/province [43]
0
0
Lombardia
Query!
Country [44]
0
0
Italy
Query!
State/province [44]
0
0
Piemonte
Query!
Country [45]
0
0
Italy
Query!
State/province [45]
0
0
Veneto
Query!
Country [46]
0
0
Netherlands
Query!
State/province [46]
0
0
Amsterdam
Query!
Country [47]
0
0
Netherlands
Query!
State/province [47]
0
0
Zwolle
Query!
Country [48]
0
0
Russian Federation
Query!
State/province [48]
0
0
Kazan
Query!
Country [49]
0
0
Russian Federation
Query!
State/province [49]
0
0
Moscow
Query!
Country [50]
0
0
Russian Federation
Query!
State/province [50]
0
0
St. Petersburg
Query!
Country [51]
0
0
Russian Federation
Query!
State/province [51]
0
0
Stavropol
Query!
Country [52]
0
0
Spain
Query!
State/province [52]
0
0
Barcelona
Query!
Country [53]
0
0
Spain
Query!
State/province [53]
0
0
Madrid
Query!
Country [54]
0
0
Spain
Query!
State/province [54]
0
0
Pamplona
Query!
Country [55]
0
0
Spain
Query!
State/province [55]
0
0
Valencia
Query!
Country [56]
0
0
Sweden
Query!
State/province [56]
0
0
Goteborg
Query!
Country [57]
0
0
Sweden
Query!
State/province [57]
0
0
Lund
Query!
Country [58]
0
0
Sweden
Query!
State/province [58]
0
0
Stockholm
Query!
Country [59]
0
0
Sweden
Query!
State/province [59]
0
0
Uppsala
Query!
Country [60]
0
0
Ukraine
Query!
State/province [60]
0
0
Dnipropetrovsk
Query!
Country [61]
0
0
Ukraine
Query!
State/province [61]
0
0
Donetsk
Query!
Country [62]
0
0
Ukraine
Query!
State/province [62]
0
0
Khmelnytskyi
Query!
Country [63]
0
0
Ukraine
Query!
State/province [63]
0
0
Kyiv
Query!
Country [64]
0
0
Ukraine
Query!
State/province [64]
0
0
Lviv
Query!
Country [65]
0
0
Ukraine
Query!
State/province [65]
0
0
Sumy
Query!
Country [66]
0
0
United Kingdom
Query!
State/province [66]
0
0
Middlesex
Query!
Country [67]
0
0
United Kingdom
Query!
State/province [67]
0
0
Surrey
Query!
Country [68]
0
0
United Kingdom
Query!
State/province [68]
0
0
Aberdeen
Query!
Country [69]
0
0
United Kingdom
Query!
State/province [69]
0
0
Bebington
Query!
Country [70]
0
0
United Kingdom
Query!
State/province [70]
0
0
Edgbaston, Birmingham
Query!
Country [71]
0
0
United Kingdom
Query!
State/province [71]
0
0
Leeds
Query!
Country [72]
0
0
United Kingdom
Query!
State/province [72]
0
0
London
Query!
Country [73]
0
0
United Kingdom
Query!
State/province [73]
0
0
Newcastle upon Tyne
Query!
Country [74]
0
0
United Kingdom
Query!
State/province [74]
0
0
Nottingham
Query!
Country [75]
0
0
United Kingdom
Query!
State/province [75]
0
0
Oxford
Query!
Country [76]
0
0
United Kingdom
Query!
State/province [76]
0
0
Preston
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Novartis Pharmaceuticals
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This was a two-arm, double-blinded, randomized, Phase III study comparing dabrafenib and trametinib combination therapy to dabrafenib administered with a placebo (dabrafenib monotherapy). Subjects with histologically confirmed cutaneous melanoma that is either Stage IIIC (unresectable) or Stage IV, and BRAF V600E/K mutation positive were screened for eligibility. Subjects who had prior systemic anti-cancer treatment in the advanced or metastatic setting were not eligible although prior systemic treatment in the adjuvant setting was allowed. Subjects were stratified according to the baseline lactate dehydrogenase level and BRAF genotype.
Query!
Trial website
https://clinicaltrials.gov/study/NCT01584648
Query!
Trial related presentations / publications
Schadendorf D, Robert C, Dummer R, Flaherty KT, Tawbi HA, Menzies AM, Banerjee H, Lau M, Long GV. Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers. Eur J Cancer. 2021 Aug;153:234-241. doi: 10.1016/j.ejca.2021.05.005. Epub 2021 Jul 2. Syeda MM, Wiggins JM, Corless BC, Long GV, Flaherty KT, Schadendorf D, Nathan PD, Robert C, Ribas A, Davies MA, Grob JJ, Gasal E, Squires M, Marker M, Garrett J, Brase JC, Polsky D. Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study. Lancet Oncol. 2021 Mar;22(3):370-380. doi: 10.1016/S1470-2045(20)30726-9. Epub 2021 Feb 12. Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, Chiarion Sileni V, Schachter J, Garbe C, Bondarenko I, Gogas H, Mandala M, Haanen JBAG, Lebbe C, Mackiewicz A, Rutkowski P, Nathan PD, Ribas A, Davies MA, Flaherty KT, Burgess P, Tan M, Gasal E, Voi M, Schadendorf D, Long GV. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. N Engl J Med. 2019 Aug 15;381(7):626-636. doi: 10.1056/NEJMoa1904059. Epub 2019 Jun 4. Long GV, Grob JJ, Nathan P, Ribas A, Robert C, Schadendorf D, Lane SR, Mak C, Legenne P, Flaherty KT, Davies MA. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol. 2016 Dec;17(12):1743-1754. doi: 10.1016/S1470-2045(16)30578-2. Epub 2016 Nov 16. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion-Sileni V, Lebbe C, Mandala M, Millward M, Arance A, Bondarenko I, Haanen JB, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, DeMarini DJ, Irani JG, Swann S, Legos JJ, Jin F, Mookerjee B, Flaherty K. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015 Aug 1;386(9992):444-51. doi: 10.1016/S0140-6736(15)60898-4. Epub 2015 May 31. Schadendorf D, Amonkar MM, Stroyakovskiy D, Levchenko E, Gogas H, de Braud F, Grob JJ, Bondarenko I, Garbe C, Lebbe C, Larkin J, Chiarion-Sileni V, Millward M, Arance A, Mandala M, Flaherty KT, Nathan P, Ribas A, Robert C, Casey M, DeMarini DJ, Irani JG, Aktan G, Long GV. Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. Eur J Cancer. 2015 May;51(7):833-40. doi: 10.1016/j.ejca.2015.03.004. Epub 2015 Mar 17. Menzies AM, Ashworth MT, Swann S, Kefford RF, Flaherty K, Weber J, Infante JR, Kim KB, Gonzalez R, Hamid O, Schuchter L, Cebon J, Sosman JA, Little S, Sun P, Aktan G, Ouellet D, Jin F, Long GV, Daud A. Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial. Ann Oncol. 2015 Feb;26(2):415-21. doi: 10.1093/annonc/mdu529. Epub 2014 Nov 18. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion Sileni V, Lebbe C, Mandala M, Millward M, Arance A, Bondarenko I, Haanen JB, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, DeMarini DJ, Irani JG, Casey M, Ouellet D, Martin AM, Le N, Patel K, Flaherty K. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014 Nov 13;371(20):1877-88. doi: 10.1056/NEJMoa1406037. Epub 2014 Sep 29.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Novartis Pharmaceuticals
Query!
Address
0
0
Novartis Pharmaceuticals
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT01584648
Download to PDF